ストックスクリーナーアプリを入手
477.91
0.85%
3.74
アフターアワーズ：
481.63
3.72
+0.78%
前日終値:
$474.17
開ける：
$474.09
24時間の取引高:
1.08M
Relative Volume:
0.77
時価総額：
$121.25B
収益：
$11.74B
当期純損益:
$3.68B
株価収益率:
33.68
EPS:
14.1888
ネットキャッシュフロー:
$3.34B
1週間 パフォーマンス:
+3.70%
1か月 パフォーマンス:
+3.31%
6か月 パフォーマンス:
+3.77%
1年 パフォーマンス:
+8.52%
1日の値動き範囲:
$469.50
$479.50
1週間の範囲:
$458.31
$485.00
52週間の値動き範囲:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.75 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.58 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
Barclays Upgrades Vertex Pharmaceuticals (VRTX) with Increased P - GuruFocus
Here’s Why Hardman Johnston Global Equity Strategy Sold Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Barlow Wealth Partners Inc. Sells 21,078 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Physician Views Results: Vertex's Journavx impresses in acute pain, as case for chronic comes into focus - FirstWord Pharma
VRTX Stock Surges 6.1% With A 5-day Winning Spree On Analyst Upgrades - Trefis
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Leader With 8% Potential Upside - DirectorsTalk Interviews
Vertex Pharmaceuticals (VRTX) Sees Price Target Increase by UBS to $545 | VRTX Stock News - GuruFocus
Best Biotech Stocks To Follow NowJanuary 26th - MarketBeat
Vertex Pharmaceuticals price target raised to $545 from $535 at UBS - TipRanks
Lbp Am Sa Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
UniSuper Management Pty Ltd Has $8.03 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AMF Tjanstepension AB Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Analyst Upgrades And CASGEVY Approval - Yahoo Finance
Y Intercept Hong Kong Ltd Takes $10.88 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
How Evolving Analyst Assumptions Are Reshaping The Story For Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Resona Asset Management Co. Ltd. Sells 4,351 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jennison Associates LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Strs Ohio Has $31.58 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Breaking Down Vertex Pharmaceuticals: 12 Analysts Share Their Views - Benzinga
Vertex Pharmaceuticals (VRTX) Sees Raised Price Target by Everco - GuruFocus
Wall Street Analysts Think Vertex (VRTX) Is a Good Investment: Is It? - Yahoo Finance
Teacher Retirement System of Texas Sells 3,725 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Up 30%, Analyst Upgrades to Outperform with $546 Target - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Inogen (INGN) - The Globe and Mail
Cystic Fibrosis Therapeutics Market to Reach US$35.09 Billion - openPR.com
RBC Capital Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
FDA Grants Orphan Status to Vertex Pharmaceuticals' (VRTX) Treat - GuruFocus
Vertex Pharmaceuticals (VRTX) Upgraded on Strong Cystic Fibrosis Franchise - GuruFocus
Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil - CNBC
Vertex Pharma Stock Is Quietly Going Off – But Is It Actually Worth Your Money? - AD HOC NEWS
RBC Capital Upgrades Vertex Pharmaceuticals (VRTX) Rating to 'Ou - GuruFocus
Vertex Pharma upgraded at RBC Capital Markets citing upside in 2026 - Seeking Alpha
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Outperform at Royal Bank Of Canada - MarketBeat
Boston Common Asset Management LLC Sells 5,164 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Neuropathic Pain Market to Reach US$ 18.45 Billion by 2033 at 8.9% - openPR.com
Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)? - Yahoo Finance
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug - MSN
Responsibility | Grants and Giving - Vertex Pharmaceuticals
Promising Biotech Stocks To ConsiderJanuary 21st - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Wealth Enhancement Advisory Services LLC - MarketBeat
Rakuten Investment Management Inc. Makes New $94.96 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bailard Inc. - MarketBeat
Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) - The Globe and Mail
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th - Business Wire
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Americana Partners LLC Buys 12,134 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
2.59%
4.02%
大文字化:
|
ボリューム (24 時間):